drugset / Trial / NCT04314362
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
RandomizedParallel-groupSingle-blindTreatment
Summary
Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.
Timeline
- Start
- 2020-07-14
- Primary completion
- 2021-01-06
- Completion
- 2021-01-06
Outcome
Met primary endpoint
release “statistically significant improvement in a sign, Meibomian Glands Yielding Liquid Secretion (MGYLS), and symptomatic benefit in Ocular Surface Disease Index (OSDI © ) in CELESTIAL” azuraophthalmics.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZR-MD-001 | Unknown | 1 % | — |